T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis
T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis
Recruiting · NCT07152782 · Registry updated 2026-09-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis | Breast Cancer With Brain Metastasis; HER2-positive Breast Cancer | Recruiting | Phase 2 | 2026-09-28 | NCT07152782 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Fudan University | 653 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Fudan University Shanghai Cancer Center | Shanghai | China | 128 |